Protecting Americans from Unsafe Drugs Act of 2026

Bill Summary: Protecting Americans from Unsafe Drugs Act of 2026

Overview

The Protecting Americans from Unsafe Drugs Act of 2026 (H.R. 7980) is a legislative effort to expand the authority of federal regulatory bodies to manage the recall and distribution of dangerous pharmaceutical products. The bill focuses on broadening the scope of existing law to ensure that "drugs" in general—not just "controlled substances"—can be subject to immediate cease-distribution orders and recalls.

Purpose and Intent

The primary intent of this bill is to close a regulatory gap in the Federal Food, Drug, and Cosmetic Act. Currently, certain stringent recall and notification procedures are specifically targeted at "controlled substances." By expanding this terminology, the bill aims to provide the government with more flexible and comprehensive tools to remove unsafe medications from the market quickly, regardless of whether they are classified as controlled substances.

Key Provisions

The bill makes several technical but significant amendments to existing laws:

• Expansion of Scope: Amends Section 569D of the Federal Food, Drug, and Cosmetic Act to replace references to "controlled substances" with the broader term "drugs." This ensures that the legal mechanisms for ordering the cessation of distribution and initiating recalls apply to a wider array of pharmaceutical products.
• Broadened Authority: Modifies the law to explicitly include the Director of the Center for Biologics Evaluation and Research (CBER) (or their senior officials) in the process of issuing these orders, expanding the oversight capacity for biological drug products.
• Import/Export Restrictions: Updates Section 801(a) of the Federal Food, Drug, and Cosmetic Act to ensure that any drug (not just a controlled substance) subject to a recall order is restricted from being imported into or exported from the United States.

Who is Affected?

• Pharmaceutical Manufacturers and Distributors: Companies will be subject to broader federal authority regarding the mandatory recall and cessation of distribution for a wider range of products.
• Federal Regulatory Agencies: The FDA and the Center for Biologics Evaluation and Research (CBER) gain increased legal standing to act swiftly against unsafe drugs.
• The General Public: Consumers may benefit from faster removal of unsafe or contaminated medications from the pharmacy supply chain.

Procedural Status

• Introduced: March 18, 2026
• Current Status: Referred to the House Committee on Energy and Commerce for further review.